Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial

Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial

Abstract There are few studies focus on post-neoadjuvant treatment in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-)/lymph node-positive (LN+) breast cancer, a multi-center, open-label, randomized, controlled phase III trial was conducted to evaluate pathol...

Full description

Bibliographic Details
Main Authors: Yang Yang, Yingjian He, Zhaoqing Fan, Xue Chen, Yiqiang Liu, Chao Zhang, Hongchuan Jiang, Xin Wang, Xiang Wang, Fei Xie, Shu Wang, Bin Luo, Hua Kang, Tao Wang, Zefei Jiang, Peng Yuan, Binhe Xu, Ling Xu, Yinhua Liu, Jinfeng Li, Yuntao Xie, Tianfeng Wang, Tao Ouyang
Format: Article
Language:English
Published: Nature Portfolio 2023-06-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-023-00553-y

Internet

https://doi.org/10.1038/s41523-023-00553-y

Similar Items